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Reevaluating Humeral Length for the
Detection of Fetal Trisomy 21
Diana L. Gray, MD, Jeffrey M. Dicke, MD, Rachel Dickerson, MD,
Carolyn McCourt, MD, Anthony O. Odibo, MD, MSCE
Objective. The purpose of this study was to analyze humeral length (HL) in a normal population and
to compare that with HL in a population of fetuses with trisomy 21 to determine the most efficient
discriminating parameters for diagnostic accuracy. Methods. A nested case-control study comparing
HLs from a normal population and a population of fetuses with trisomy 21 was conducted. Humeral
length was regressed against gestational age for a consecutive well-dated population of normal sin-
gleton gestations presenting to the Washington University School of Medicine prenatal diagnosis units
over a 5-year period. A second population of well-dated pregnancies with trisomy 21 diagnosed either
prenatally or postnatally was also selected on the basis of the same criteria, except that anomalous
fetuses were included. Various discriminating thresholds for a short HL were compared for efficiency
in the detection of trisomy 21. These included the following: observed/expected HL (≤0.89), biparietal
diameter/HL greater than 1.3, 1.4, 1.5, 1.6, 1.7, 1.75, 1.8, and 1.85 SD above the mean for gestation,
HL less than 0.8 or less than 0.9 multiple of the median, and HL less than the fifth percentile for ges-
tation. Results. A total of 620 normal pregnancies and 32 with trisomy 21 were extracted from the
database. A receiver operating characteristic curve revealed HL less than the fifth percentile as the opti-
mal discriminator for trisomy 21 detection (area under the receiver operating characteristic curve =
0.80). The positive likelihood ratio (LR+) was greatest (25.0) with HL less than the fifth percentile. When
HL was considered in isolation without other sonographic markers of trisomy 21, the LR+ was 6.3.
Conclusions. Humeral length less than the fifth percentile was the most effective discriminator among
the many studied. Key words: Down syndrome; fetal trisomy 21; humeral length; prenatal diagnosis;
sonography. 
Abbreviations
BPD, biparietal diameter; FL, femur length; FPR, false-
positive rate; GA, gestational age; HL, humeral length;
LMP, last menstrual period; LR, likelihood ratio; MoM,
multiple of the median
hortened humeri and femora are well-recognized
sonographic markers for fetal trisomy 21.1–8 Most
investigations of humeral length (HL) in the detec-
tion of fetal trisomy 21 have shown superior per-
formance of this marker compared to shortened femur
length (FL). The likelihood ratios (LR) cited by Nyberg et
al9 were 5.1 for a shortened humerus compared with 1.5
for a shortened femur when used as isolated sonographic
markers for trisomy 21. A study by Bromley et al4 yielded
an LR of 5.8 for a shortened humerus compared with 1.2
for a shortened femur. Various discriminating thresholds
for a shortened humerus have been shown as effective
markers for fetal trisomy 21, including observed to pre-
dicted HL,2,4 multiples of the median (MoMs),6 and HL
less than the fifth percentile for gestation.1 However,
another study by Vergani et al10 that included a meta-
analysis of studies on HL in the detection of fetal trisomy
21 concluded that the utility of this marker was inconsis-
tent. This group concluded that only institutions with
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locally generated regression equations and docu-
mented predictive ability of this marker should be
using it as a screening test for trisomy 21. The
objective of the investigation described herein was
to analyze HL in a normal population of patients
at our center and to compare that with a popula-
tion of fetuses with trisomy 21 to determine the
most efficient discriminating parameters for diag-
nostic accuracy.
Materials and Methods
This was a nested case-control study comparing
fetal HLs from a normal population with those
from a population of fetuses with trisomy 21. The
study was approved by the Washington University
School of Medicine Institutional Review Board for
Human Studies. Humeral length was measured
for a consecutive, well-dated, normal population
of 1068 singleton gestations presenting to the
Washington University School of Medicine (WUSM)
prenatal diagnosis units over a 5-year period from
May 26, 1994, through August 6, 1999. These preg-
nancies were selected from the division’s comput-
erized database on the basis of the following
inclusion criteria: singleton gestations dated by a
known first day of the last menstrual period (LMP)
with no oral contraceptive use within the 2
months before conception and positive urine
pregnancy test results within 5 weeks of the LMP
date, a known conception date, or a first-trimester
crown-rump length consistent with 5 days of the
expected gestation by LMP. Cases were excluded if
the pregnancy ended in abortion or stillbirth or if
a fetal anomaly was diagnosed before or after
birth. These cases were excluded because it is well
known that pregnancies destined for sponta-
neous abortion or stillbirth very frequently have
abnormal growth patterns. All fetal structural
anomalies identified in our prenatal sonography
units, from anencephaly to minor dysmor-
phisms, are prospectively coded and entered
into the database. If a fetal anomaly code was
entered for a particular pregnancy, that preg-
nancy was excluded from the group used to gen-
erate the normal HL growth curve. Intrauterine
growth restriction is also coded as an anomaly;
thus, such pregnancies were excluded. A single
sonographic examination in which HL was mea-
sured was selected for those pregnancies in which
multiple examinations occurred; the process of
selection involved selecting HL measurements
from weeks in which the data to generate the
normal curve were limited, ensuring that no
overlap with a previously included pregnancy
occurred. From the same period and thus the
same overall population, a second group of well-
dated pregnancies with trisomy 21 diagnosed
either prenatally or postnatally was also selected
on the basis of the same criteria, except that
structurally anomalous fetuses were allowed in
this study group. There were no significant differ-
ences in demographic characteristics between
the two populations studied (Table 1). The HLs
of the two populations were then compared, and
various discriminating thresholds were studied.
Sonographic measurements in both popula-
tions were made with similar real-time state-of-
the-art equipment, including Acuson 128XP
(Siemens Medical Solutions, Mountain View, CA),
Sonoline Elegra (Siemens Medical Solutions,
Malvern, PA), Ultramark 8 (Philips Healthcare,
Bothell, WA), and a GE 3000 (GE Healthcare,
Milwaukee, WI). The HL was measured in the stan-
dardized fashion inclusive of the diaphyseal por-
tion of the bone. The measurements were made
by experienced sonographers or sonologists who
were unaware of the fetal diagnosis or karyotype
at the time of measurement.
Using least squares analysis, HL was regressed
against gestational age (GA) for the normal pop-
ulation studied. Discriminating thresholds for a
shortened HL were compared for efficiency in
the detection of fetal trisomy 21 using receiver
operating characteristic curves. These thresholds
included the following: observed/expected HL
(≤0.89), biparietal diameter (BPD)/HL greater
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Table 1. Demographic Characteristics of the Study
Populations
Trisomy 21 No Trisomy 21
Characteristic (n = 32) (n = 620) P
Mean age ± SD, y 35.7 ± 5.3 36.6 ± 4.2 .37
Race, n (%)
White 26 (84) 451 (73)
Black 1 (3) 54 (9)
Hispanic 1 (3) 10 (2) .59
Asian 1 (3) 4 (1)
Other 3 (7) 91 (15)
Mean GA ± SD at 20.4 ± 5.6 18.5 ± 1.8 .06
scanning, wk
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than 1.3, 1.4, 1.5, 1.6, 1.7, 1.75, 1.8, and 1.85 SD
above the mean for gestation, HL less than 0.8 or
0.9 MoM, and HL less than the fifth percentile.
Statistical methods, including χ2 and t tests, were
used for categorical and continuous variables,
respectively. All analyses were performed using
Stata 9.0 SE (StataCorp, College Station TX).
Results
For the normal population, 620 pregnancies in the
database met inclusion criteria. These pregnan-
cies were well distributed from 12 to 40 weeks’
gestation. The regression equation for HL versus
GA with the best fit for the normal population
was the following: HL = –3.527 + 0.417 (GA) –
0.004 (GA)2. The fit was excellent, as evidenced by
the R2 value, which was 0.97 (Figure 1). Thirty-
two fetuses with trisomy 21 met inclusion crite-
ria and constituted the trisomy 21 population.
There were no significant differences in demo-
graphic characteristics between the two popula-
tions studied (Table 1). Receiver operating
characteristic analysis revealed that HL less than
the fifth percentile was the most efficient dis-
criminator (Figure 2). Mean and fifth percentile
HLs by gestation are presented in Table 2.
When short HL was tested for effectiveness in
the detection of fetal trisomy 21 in our popula-
tion, it was found to be quite effective. The effi-
ciency parameters for the most discriminating
HL thresholds are found in Table 3. Humeral
length less than the fifth percentile for GA was
found to be the most efficient discriminator, with
12 of 32 fetuses with trisomy 21 detected, for sen-
sitivity of 37.5%, a positive screen rate (false-pos-
itive rate [FPR]) of 1.5%, a positive predictive
value of 57% (1 per 1.75), and a positive LR (LR+)
of 25.0. The negative LR (LR–) was 0.6. In
descending order, the next most effective thresh-
olds were observed/expected HL of 0.89 or less,
with an LR+ of 15.5; HL less than 0.9 MoM, with
an LR+ of 9.3; and BPD/HL greater than 1.7 or
greater than 1.75, both with LR+ values of 3.4.
The less effective discriminating thresholds
included all of the other variations of BPD/HL
(>1.3–1.85) and HL less than 0.8 MoM, with LR+
values ranging from 0 to 2.9. All screening effi-
ciency parameters for these thresholds are listed
in Table 4.
When HL less than the fifth percentile was eval-
uated as an isolated finding in the population of
fetuses with trisomy 21, 3 of 32 (9.4%) were found
to have this finding in the absence of other sono-
graphic markers of trisomy 21. In the normal
population, 9 of 620 (1.5%) had a shortened HL.
Therefore, as an isolated sonographic marker of
fetal trisomy 21, the LR+ for HL less than the fifth
percentile for gestation was 6.3. 
Discussion
Comparing shortened HL less than the fifth per-
centile as a sonographic marker of fetal trisomy
21 to a previous study of shortened FL from our
institution by Dicke et al,5 we found that HL less
J Ultrasound Med 2009; 28:1325–1330 1327
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Figure 1. Humeral length regression curve: HL = –3.527 +
0.417 (GA) – 0.004 (GA)2. CI indicates confidence interval.
Figure 2. Receiver operating characteristic curve comparing
BPD/HL greater than 1.7, 1.75, and greater than 1.8 with fifth
percentile, less than 0.9 MoM, and abnormal observed
(Obs)/expected (Exp) HL (≤0.89).
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than the fifth percentile performed better as a
predictor of fetal trisomy 21. The sensitivity of HL
less than the fifth percentile of 37.5%, FPR of
1.5%, positive predictive value of 1 per 1.75, and
LR+ of 25.0 were substantially better than the
parameters for a shortened femur using BPD/FL
greater than 1.5 SD (sensitivity of 18%, FPR of
4%, positive predictive value of 1 per 169, and
LR+ of 4.5). The low FPR of 1.5% indicates that
the nomogram we generated for HL was very
strict in the definition of defining a shortened
femur. This is not a limitation of the study
because it should reduce the anxiety and further
testing provoked by screening tests with higher
FPRs. In our previous study of FL and trisomy 21,
the fetuses with a shortened FL as the only find-
ing were not segregated from the population of
fetuses with trisomy 21 and multiple sonograph-
ic findings. Hence, the performance of HL as an
isolated marker for the detection of trisomy 21
cannot be compared to FL in isolation.
Comparisons with previous studies of short-
ened HL can be found in Table 5. Rodis et al1 pub-
lished the first study of the effectiveness of HL as
a marker for fetal trisomy 21 in 1991. This inves-
tigation also used HL less than the fifth percentile
as the discriminating threshold in a small popu-
lation of fetuses with trisomy 21 (n = 11) with a
resulting LR+ of 12.8 and an FPR of 5%. Our study
was second in size for the number of fetuses with
trisomy 21 to a 1993 study published by Nyberg
et al,2 which had 45 fetuses with trisomy 21 and
yielded sensitivity of 24.4%, an FPR of 4.5%, and
an LR+ of 5.4. The LR+ values of 25.0 when not
controlled for other markers of trisomy 21 and
6.3 when found in isolation for this study com-
pare favorably with those from the other studies
listed in Table 5. One possible limitation of the
1328 J Ultrasound Med 2009; 28:1325–1330
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Table 3. Most Effective Discriminating Thresholds
Sens, % (95% CI) Spec, % (95% CI) PPV, % NPV, %
Parameter (Tri 21 = 32) (Normal = 620) FPR, % (95% CI) (95% CI) LR+ LR–
HL <5th 37.5 98.5 1.5 57 97 25.0 0.6
(21–56) (97–99) (34–78) (95–98)
HL <5th (isolated) 9.4 98.5 1.5 25 95.5 6.3 0.9
(2–25) (97–99) (6–57) (94–97)
HL <0.9 MoM 37.5 96 4.0 34 97 9.3 0.7
(21–56) (94–98) (19–52) (95–98)
BPD/HL >1.7 47 86 14.0 15 97 3.4 0.6
(29–65) (83–89) (9–23) (95–98)
BPD/HL >1.75 34 90 10.0 15 96 3.4 0.7
(19–53) (87–92) (8–26) (95–98)
Obs/Exp HL ≤0.89 31 98 2.0 40 97 15.5 0.7
(16–50) (96–99) (21–61) (95–98)
CI indicates confidence interval; NPV, negative predictive value; Obs/Exp, observed/expected; PPV, positive predictive value; Sens = sensitivity;
Spec = specificity; and Tri 21, trisomy 21.
Table 2. Humeral Length at 5th and 50th Percentiles
by Gestation 
HL, cm
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study was that most of the HL measurements
were made in the second trimester between 14
and 22 weeks. The regression model included
fetuses at all weeks’ gestation, however. The sec-
ond-trimester time frame is that in which most
screening for fetal trisomy 21 occurs; therefore,
the findings are reliable. As a result of this study,
we will incorporate the use of HL shortening in
the screening protocol for trisomy 21 when
appropriate in our prenatal diagnosis units. It
will be used in our clinical practice in addition to
other sonographic markers for trisomy 21, such as
a thickened nuchal skin fold, by factoring the HL
LR+ into the a priori risk for trisomy 21. The a pri-
ori risk may have been generated on the basis of
maternal age, serum screening, or first-trimester
screening. As did Vergani et al,10 we urge caution
when using biometric markers as screening tools
for fetal syndromes. The nomograms and abnor-
mal thresholds for biometric markers are most
accurate if they have been generated in the local
center where they will be used or systematically
verified as effective in that population. Hence, as
is the case whenever biometric parameters are
used to screen for fetal disorders, the applicabil-
ity of these possible markers for general use may
be limited. Such markers are best applied in a
tertiary level prenatal diagnosis center that has
studied their use as predictors for the fetal disor-
ders in question.
J Ultrasound Med 2009; 28:1325–1330 1329
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Table 4. Least Effective Discriminating Thresholds
Sens, % (95% CI) Spec, % (95% CI) PPV, % NPV, %
Parameter (Tri 21 = 32) (Normal = 620) FPR, % (95% CI) (95% CI) LR+ LR–
BPD/HL >1.3  100 1.0 99 5.0 100 1.0 0
(89–100) (0.36–2.1) (3.4–6.9) (54–100)
BPD/HL >1.4  100 9.2 90.8 5.4 100 1.1 0
(89–100) (7.0–11.7) (3.7–7.5) (94–100)
BPD/HL >1.5 97 37.9 62.1 7.5 99.6 1.6 0.1
(84–99.9) (34–41.9) (5.1–10.4) (97.7–100)
BPD/HL >1.6 84.4 64.8 35.2 11.0 98.8 2.4 0.2
(67.2–94.7) (60.9–68.6) (7.4–15.6) (97.2–99.6)
BPD/HL >1.8  18.8 93.5 6.5 13.0 95.7 2.9 0.9
(7.2–36.4) (91.3–95.4) (4.9–26.3) (93.8–97.2)
BPD/HL >1.85 3.1 96.6 3.4 4.5 95.1 0.9 1.0
(0.0–16.2) (94.9–97.9) (0.1–22.8) (93.1–96.6)
HL <0.8 MoM 3.1 100 0 100 95.2 0 1.0
(0.0–16.2) (99.4–100) (2.5–100) (93.3–96.7)
CI indicates confidence interval; NPV, negative predictive value; PPV, positive predictive value; Sens = sensitivity; Spec = specificity; and
Tri 21, trisomy 21.
Table 5. Comparison With Previous Studies of Short HL 
Sens, %
Reference Discriminator (Tri 21 Detected/Total Tri 21) FPR, % LR+
Rodis et al1 <5th 64 (7/11) 5 12.8
Nyberg et al2 Obs/Exp ≤0.89 24.4 (11/45) 4.5 5.4
Bahado-Singh et al6 Obs/Exp <0.92 55 (6/11) 9 6.1
Vintzileos et al7 Obs/Exp <0.89 48 (10/21) 2 12.0
Benacerraf et al11 Obs/Exp <0.9 50 (12/24) 6.25 8.0
This study <5th 37.5 (12/32) 1.5 25.0
9.4 (3/32) (isolated) 1.5 6.3
Obs/Exp indicates observed/expected; Sens, sensitivity; and Tri 21, trisomy 21.
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